|
MechanismP2Y12 receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date17 Nov 1997 |
100 Clinical Results associated with Mylan dura GmbH
0 Patents (Medical) associated with Mylan dura GmbH
100 Deals associated with Mylan dura GmbH
100 Translational Medicine associated with Mylan dura GmbH